Responses
Extended reports
Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFκB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis
Compose a Response to This Article
Other responses
No responses have been published for this article.